254 related articles for article (PubMed ID: 34561272)
21. Serous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?
Roh MH; Kindelberger D; Crum CP
Am J Surg Pathol; 2009 Mar; 33(3):376-83. PubMed ID: 19011565
[TBL] [Abstract][Full Text] [Related]
22. GATA3 as a master regulator for interactions of tumor-associated macrophages with high-grade serous ovarian carcinoma.
El-Arabey AA; Denizli M; Kanlikilicer P; Bayraktar R; Ivan C; Rashed M; Kabil N; Ozpolat B; Calin GA; Salama SA; Abd-Allah AR; Sood AK; Lopez-Berestein G
Cell Signal; 2020 Apr; 68():109539. PubMed ID: 31935430
[TBL] [Abstract][Full Text] [Related]
23. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
[TBL] [Abstract][Full Text] [Related]
24. Characterization of MicroRNA-200 pathway in ovarian cancer and serous intraepithelial carcinoma of fallopian tube.
Yang J; Zhou Y; Ng SK; Huang KC; Ni X; Choi PW; Hasselblatt K; Muto MG; Welch WR; Berkowitz RS; Ng SW
BMC Cancer; 2017 Jun; 17(1):422. PubMed ID: 28623900
[TBL] [Abstract][Full Text] [Related]
25. DFMO and 5-Azacytidine Increase M1 Macrophages in the Tumor Microenvironment of Murine Ovarian Cancer.
Travers M; Brown SM; Dunworth M; Holbert CE; Wiehagen KR; Bachman KE; Foley JR; Stone ML; Baylin SB; Casero RA; Zahnow CA
Cancer Res; 2019 Jul; 79(13):3445-3454. PubMed ID: 31088836
[TBL] [Abstract][Full Text] [Related]
26. A FXYD5/TGF‑β/SMAD positive feedback loop drives epithelial‑to‑mesenchymal transition and promotes tumor growth and metastasis in ovarian cancer.
Bai Y; Li LD; Li J; Chen RF; Yu HL; Sun HF; Wang JY; Lu X
Int J Oncol; 2020 Jan; 56(1):301-314. PubMed ID: 31746425
[TBL] [Abstract][Full Text] [Related]
27. B7-H3 Suppresses Antitumor Immunity via the CCL2-CCR2-M2 Macrophage Axis and Contributes to Ovarian Cancer Progression.
Miyamoto T; Murakami R; Hamanishi J; Tanigaki K; Hosoe Y; Mise N; Takamatsu S; Mise Y; Ukita M; Taki M; Yamanoi K; Horikawa N; Abiko K; Yamaguchi K; Baba T; Matsumura N; Mandai M
Cancer Immunol Res; 2022 Jan; 10(1):56-69. PubMed ID: 34799346
[TBL] [Abstract][Full Text] [Related]
28. Tumor-associated macrophages promote ovarian cancer cell migration by secreting transforming growth factor beta induced (TGFBI) and tenascin C.
Steitz AM; Steffes A; Finkernagel F; Unger A; Sommerfeld L; Jansen JM; Wagner U; Graumann J; Müller R; Reinartz S
Cell Death Dis; 2020 Apr; 11(4):249. PubMed ID: 32312959
[TBL] [Abstract][Full Text] [Related]
29. A genetically engineered ovarian cancer mouse model based on fallopian tube transformation mimics human high-grade serous carcinoma development.
Sherman-Baust CA; Kuhn E; Valle BL; Shih IeM; Kurman RJ; Wang TL; Amano T; Ko MS; Miyoshi I; Araki Y; Lehrmann E; Zhang Y; Becker KG; Morin PJ
J Pathol; 2014 Jul; 233(3):228-37. PubMed ID: 24652535
[TBL] [Abstract][Full Text] [Related]
30. [Preliminary study on the relationship between tubal intraepithelial carcinoma of the fimbria and pelvic high-grade serous carcinoma].
Liang Y; Chen XD; Lü BJ; Zhou CY; Zhang XF; Shi HY
Zhonghua Fu Chan Ke Za Zhi; 2011 Oct; 46(10):724-8. PubMed ID: 22321343
[TBL] [Abstract][Full Text] [Related]
31. Changes in the Extracellular Matrix Are Associated With the Development of Serous Tubal Intraepithelial Carcinoma Into High-Grade Serous Carcinoma.
van der Steen SCHA; Bulten J; Van de Vijver KK; van Kuppevelt TH; Massuger LFAG
Int J Gynecol Cancer; 2017 Jul; 27(6):1072-1081. PubMed ID: 28333845
[TBL] [Abstract][Full Text] [Related]
32. [Expansion of secretory cells in the fallopian tubal epithelium in the early stages of the pathogenesis of ovarian serous carcinomas].
Asaturova AV; Ezhova LS; Faizullina NM; Adamyan LV; Khabas GN; Sannikova MV
Arkh Patol; 2017; 79(3):10-18. PubMed ID: 28631711
[TBL] [Abstract][Full Text] [Related]
33. Serous tubal in situ carcinoma (STIC) in primary peritoneal serous carcinomas.
Horn LC; Kafkova S; Leonhardt K; Kellner C; Einenkel J
Int J Gynecol Pathol; 2013 Jul; 32(4):339-44. PubMed ID: 23722505
[TBL] [Abstract][Full Text] [Related]
34. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship.
Kindelberger DW; Lee Y; Miron A; Hirsch MS; Feltmate C; Medeiros F; Callahan MJ; Garner EO; Gordon RW; Birch C; Berkowitz RS; Muto MG; Crum CP
Am J Surg Pathol; 2007 Feb; 31(2):161-9. PubMed ID: 17255760
[TBL] [Abstract][Full Text] [Related]
35. Alternatively-Activated Macrophages Upregulate Mesothelial Expression of P-Selectin to Enhance Adhesion of Ovarian Cancer Cells.
Carroll MJ; Fogg KC; Patel HA; Krause HB; Mancha AS; Patankar MS; Weisman PS; Barroilhet L; Kreeger PK
Cancer Res; 2018 Jul; 78(13):3560-3573. PubMed ID: 29739756
[TBL] [Abstract][Full Text] [Related]
36. Transforming growth Factor-Beta-Induced Protein (TGFBI)/(βig-H3): a matrix protein with dual functions in ovarian cancer.
Ween MP; Oehler MK; Ricciardelli C
Int J Mol Sci; 2012; 13(8):10461-10477. PubMed ID: 22949874
[TBL] [Abstract][Full Text] [Related]
37. FBLN5 is targeted by microRNA‑27a‑3p and suppresses tumorigenesis and progression in high‑grade serous ovarian carcinoma.
Li R; Wu H; Jiang H; Wang Q; Dou Z; Ma H; Yan S; Yuan C; Yang N; Kong B
Oncol Rep; 2020 Nov; 44(5):2143-2151. PubMed ID: 32901854
[TBL] [Abstract][Full Text] [Related]
38. [Morphological features of the fimbria of the fallopian tube in pelvic serous adenocarcinoma].
Guo DH; Pang SJ; Shen Y; Li Y
Zhonghua Zhong Liu Za Zhi; 2011 Apr; 33(4):287-90. PubMed ID: 21575501
[TBL] [Abstract][Full Text] [Related]
39. Fallopian Tube Lesions in Women at High Risk for Ovarian Cancer: A Multicenter Study.
Visvanathan K; Shaw P; May BJ; Bahadirli-Talbott A; Kaushiva A; Risch H; Narod S; Wang TL; Parkash V; Vang R; Levine DA; Soslow R; Kurman R; Shih IM
Cancer Prev Res (Phila); 2018 Nov; 11(11):697-706. PubMed ID: 30232083
[TBL] [Abstract][Full Text] [Related]
40. EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients.
Rao ZY; Cai MY; Yang GF; He LR; Mai SJ; Hua WF; Liao YJ; Deng HX; Chen YC; Guan XY; Zeng YX; Kung HF; Xie D
Carcinogenesis; 2010 Sep; 31(9):1576-83. PubMed ID: 20668008
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
